JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning

Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement investors cannot afford to ignore.